Vida and CDRD collaborate on drug development

Guest Contributor
November 2, 2015

Privately held Vida Therapeutics Inc is collaborating with the Centre for Drug Research and Development (CDRD) to advance its lead drug candidate to the commercial stage and position the firm for further private sector investment. CDRD synthesized and supplied the GzmB inhibitor drug compound to be used as a target for Vida's therapeutic strategy. The Vancouver-based firm is developing VTI-2002 — a highly specific and potent inhibitor of the GzmB enzyme found in elevated levels in patients with autoimmune and chronic inflammatory diseases such as lupus, Crohn's disease and multiple sclerosis....


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.